New research in treating breast cancer<\/h3>\n
Next, she discusses 3 studies in treating metastatic breast cancer<\/a>:<\/p>\n The phase 3 SONIA clinical trial<\/a>, which was evaluating whether using hormonal therapy alone instead of in combination with targeted therapy to treat people with HR-positive, HER2-negative metastatic breast cancer impacted the benefit of the treatment. [5:00]<\/p>\n<\/li>\n The phase 3 PADA-1 clinical trial<\/a>, which used liquid biopsy<\/a> to determine which patients with HR-positive, HER2-negative metastatic breast cancer had an ESR1<\/i> mutation. Researchers then evaluated whether switching patients whose cancer had the mutation to the next line of treatment helped slow their cancer growth for longer. [5:59]<\/p>\n<\/li>\n The phase 2 X7-7 clinical trial<\/a>, which was studying whether giving capecitabine (Xeloda) to people with metastatic breast cancer for 1 week followed by 1 week off, rather than 2 weeks followed by 1 week off, was easier for patients to tolerate without impacting the treatment\u2019s benefit. [6:38]<\/p>\n<\/li>\n<\/ul>\n Finally, Dr. Flowers discusses the phase 3 SWOG S1826 clinical trial<\/a>, which was studying whether adding nivolumab (Opdivo) to chemotherapy helped reduce the risk of cancer-related death when compared with adding brentuximab (Adcetris) to chemotherapy for children and adults with stage III or IV Hodgkin lymphoma<\/a>. [12:54]<\/p>\n Disclosure information for this podcast\u2019s speakers can be found in their individual biographies linked to above.<\/p>\n Was this podcast useful?<\/i><\/b> Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript<\/a> is also available. For more information, visit the <\/i>Cancer.Net podcast page<\/i><\/a>.<\/span><\/i><\/p>\n Cancer.Net podcasts are edited for length and content. <\/i><\/p>\n![](\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/rru-henry.jpg\")
Dr. Norah Lynn Henry, the 2023 Cancer.Net Associate Editor for Breast Cancer<\/a>, discusses research in early-stage and metastatic breast cancer. First, she discusses the phase 3 NATALEE clinical trial<\/a>, which was studying whether adding the targeted therapy drug ribociclib (Kisqali) to hormonal therapy for people with hormone receptor-positive (HR-positive), HER2-negative early-stage breast cancer<\/a> could reduce their risk of recurrence. [3:13]<\/p>\n\n
Progress in treating lymphoma and multiple myeloma<\/h3>\n
![](\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/rru-flowers.png\")
Dr. Christopher Flowers, the 2023 Cancer.Net Associate Editor for Lymphoma<\/a>, describes 3 studies in treating lymphoma and multiple myeloma. First, he discusses the phase 3 ZUMA-7 clinical trial<\/a>, which was studying whether treating people with diffuse large B-cell lymphoma (DLBCL)<\/a> that came back after initial treatment using chimeric antigen receptor (CAR) T-cell therapy<\/a> instead of a stem cell transplant helped them live longer. [9:30] Next, he describes the phase 3 CARTITUDE-4 clinical trial<\/a>, which was studying whether CAR T-cell therapy could help slow or stop cancer growth in people with multiple myeloma<\/a> that was no longer responding to treatment with lenalidomide (Revlimid). [11:56]<\/p>\nAdvances in caring for people with brain tumors and von Hippel-Lindau syndrome<\/h3>\n
![](\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/rru-strowd.png\")
Dr. Roy E. Strowd, III, the 2023 Cancer.Net Associate Editor for Central Nervous System Tumors<\/a>, discusses 3 studies in treating people with brain tumors<\/a>. First, he discusses the phase 3 INDIGO clinical trial<\/a>, which was evaluating whether the targeted therapy drug vorasidenib could help people with grade 2 glioma live longer without tumor growth. [16:28] Then, he discusses the phase 1 INB-200 clinical trial<\/a>, which was evaluating the ideal dose for a new immunotherapy in treating people with newly diagnosed glioblastoma. [23:47] To conclude, Dr. Strowd describes a study<\/a> in von Hippel-Lindau syndrome<\/a> that was observing whether belzutifan (Welireg) was effective in treating brain tumors in people with this genetic condition. [25:25]<\/p>\n